Cargando…

Dexmedetomidine for Sedation of Neonates with HIE Undergoing Therapeutic Hypothermia: A Single-Center Experience

Hypoxic-ischemic encephalopathy (HIE) is a significant cause of morbidity and mortality in neonates. Therapeutic hypothermia reduces the risk of death or disability. Providing optimal sedation while neonates are undergoing therapeutic hypothermia is likely beneficial but may present therapeutic chal...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Mara, Keliana, Weiss, Michael D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical Publishers 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123058/
https://www.ncbi.nlm.nih.gov/pubmed/30186671
http://dx.doi.org/10.1055/s-0038-1669938
Descripción
Sumario:Hypoxic-ischemic encephalopathy (HIE) is a significant cause of morbidity and mortality in neonates. Therapeutic hypothermia reduces the risk of death or disability. Providing optimal sedation while neonates are undergoing therapeutic hypothermia is likely beneficial but may present therapeutic challenges. There are limited data describing the use of dexmedetomidine for sedation in patients undergoing therapeutic hypothermia. The objective of this study is to evaluate the efficacy and short-term safety of dexmedetomidine infusion for sedation in term neonates undergoing therapeutic hypothermia for HIE.